공시 • May 20
Victrex plc Announces Stepping Down of David Thomas as Non-Executive Director, Effective May 18, 2026 Victrex PLC announces that David Thomas has informed the Board that he has stepped down as a Non-executive director of the Company with immediate effect on May 18, 2026, due to ill health. David Thomas was appointed as Non-executive director in 2018. 공시 • May 12
Victrex plc Announces Interim Dividend for the Six Months Ended 31 March 2026, Payable on 26 June 2026 Victrex plc announced interim dividend for the six months ended 31 March 2026 of 13.42 pence per share will be paid on 26 June 2026 to shareholders on the register at the close of business on 29 May 2026. This dividend will be recognised in the period in which it is approved. 공시 • Feb 11
Victrex plc Announces Changes to Its Board and Committee Spirax Group plc announced the appointment of Maria Antoniou, Non-Executive Director and Chair of the Remuneration Committee, has been appointed as a Non-Executive Director of Victrex plc with effect from 1 September 2026. Victrex plc also announced the appointment of Peter Kiernan as non-executive director and David Thomas, non-executive director and Chair of the Audit Committee, will retire from the Board on 1 July 2026, and Peter will succeed David as Chair of the Audit Committee from that date. Peter Kiernan has significant experience in executive and non-executive roles. He had a 30 year career in investment banking with a focus on M&A and general corporate finance advice, including senior roles at S.G. Warburg/UBS, Goldman Sachs, Lazard and Hawkpoint Partners/Canaccord Genuity. He started his career at Peat, Marwick, Mitchell where he qualified as a Chartered Accountant. He holds an MA in Natural Sciences (Chemistry) from Cambridge University. Peter has held several advisory and non-executive positions. He currently holds senior advisory roles at Egon Zehnder and OMERS Private Equity (Europe). Prior non-executive roles include Tungsten Corporation, a public company where he was Audit Committee Chair and Senior Independent Director, Lifeways Group, a private equity owned business where he was Audit Committee Chair and Chair, and Business LDN where he was Chair of the Finance Committee. MariaAntoniou has extensive experience in both executive and non-executive roles within UK plc Boards. She is currently Chief Human Resources Officer at Morgan Advanced Materials plc and a non-executive director at FTSE 100 listed Spirax Group plc. Until last year she was a non-executive director of NATS (the National Air Traffic Service). Maria has a strong background in international industrial businesses, having worked in significant roles at Ford, Jaguar Land Rover and E.ON. Her experience spans across various sectors, including automotive, energy, and advanced materials, which gives her a comprehensive understanding of the challenges and opportunities within industries aligned to Victrex's end-markets. 공시 • Feb 06
Jakob Sigurdsson Steps Down as an Executive Director of Victrex Plc, Effective from February 6, 2026 Coats Group PLC announces that it has been notified that Jakob Sigurdsson, a Non-Executive Director of the Company, has on February 6, 2026, stepped down as an Executive Director of Victrex plc. 공시 • Oct 22
Victrex plc, Annual General Meeting, Feb 06, 2026 Victrex plc, Annual General Meeting, Feb 06, 2026. 공시 • Dec 06
Victrex plc, Annual General Meeting, Feb 07, 2025 Victrex plc, Annual General Meeting, Feb 07, 2025. 공시 • Dec 03
Victrex plc Proposes Final Dividend for the Fiscal Year 2025, Payable on 21 February 2025 Victrex plc at its AGM to be held on 7 February 2025, proposed final dividend at 46.14 pence per share (fiscal year 2024: 46.14 pence per share), with an Ex-dividend date: 23 January 2025, Record date: 24 January 2025 and Payment of final dividend: 21 February 2025. 공시 • Sep 18
Victrex plc Announces in Partnership with Maxx Orthopedics Inc, FDA Grants IDE Approval for Freedom Total Knee System with Invibio PEEK-OPTIMA Femoral Component as Staged Study Victrex plc announced that, in partnership with Maxx Orthopedics Inc, the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for Freedom Total Knee System with Invibio PEEK-OPTIMA Femoral Component, as a staged study. The study, projected to be 120 patients at clinical sites in the US, will compare using the PEEK-OPTIMA Femoral Knee Component to a controlled registry of the same system using traditional metal femoral components. The US study will build on the existing clinical trial for PEEK Knee at sites in Belgium, India and Italy, which has been progressing strongly since the first implant in 2021, with no clinical intervention. A regulatory submission in India is also expected imminently, supporting the potential for a commercial PEEK Knee in the market in 2025. 공시 • Sep 06
Victrex plc to Report Fiscal Year 2024 Results on Dec 03, 2024 Victrex plc announced that they will report fiscal year 2024 results on Dec 03, 2024 공시 • May 15
Victrex plc Announces Interim Dividend , Payable on June 28, 2024 Victrex plc announced that an interim dividend of 13.42 pence per share (First half 2023: 13.42 pence) will be paid on 28 June 2024 to shareholders on the register at the close of business on 31 May 2024. This dividend will be recognised in the period in which it is approved. 공시 • Mar 15
Victrex plc Appoints Urmi Prasad Richardson as Non-Executive Director, Effective from May 1, 2024 Victrex plc announced that Urmi Prasad Richardson has been appointed as a non-executive director of the Board, effective from May 1, 2024. Urmi has a wealth of global experience in executive and non-executive roles over a 25 year period. She has a particular focus on science, medical and innovation based businesses. Urmi is currently President EMEA of Thermo Fisher Scientific, a world leader in serving science, with products which help accelerate life science research and improve patient health. Her executive career includes roles at The Linde Group, where she was Global Head of Healthcare, at Novartis and Foundation Medicine (a Roche company). She started her career with G.D. Searle (a Pfizer company) and has worked throughout Europe and the US. Urmi has extensive experience in strategy, business development and product commercialisation in Europe, Asia and North America. Urmi holds a number of advisory Board roles at unlisted organizations in the sectors of longevity, blockchain, and targeted therapy in oncology. Her previous non-executive roles include Linde Healthcare. 공시 • Feb 27
Victrex plc to Report First Half, 2024 Results on May 13, 2024 Victrex plc announced that they will report first half, 2024 results on May 13, 2024 공시 • Feb 09
Victrex plc Provides Earnings Guidance for the First Half and Full Year of Fiscal Year 2024 Victrex plc provided earnings guidance for the first half and full year of fiscal year 2024. First half revenue is expected to be lower than the prior year period.The Group previously communicated that progress in revenue for fiscal year 2024. 공시 • Oct 14
Victrex Announces New Product Grade Launch, Victrex Pharmaceutical Contact (PC)101 (VICTREX PC101), Developed Exclusively for the Drug Delivery Device Market Victrex plc have launched a new product grade developed exclusively for Drug Delivery and Pharmaceutical Contact applications. VICTREX PC101™ meets the highest levels of Industry biocompatibility certification for USP Class VI and also meets industry standards such as USP 661 for use in non-implantable pharmaceutical contact applications. This material is available in granules and film and adds value to pharmaceutical production companies and drug delivery device manufacturers by providing access to assured materials for equipment or devices. This has the potential to save them cost, time and reduce risk, ultimately streamlining the commercialisation of their own products. VICTREX PC101™ is a PEEK-based material ideally suited to non-implantable Pharmaceutical contact and drug delivery applications for less than 24-hour tissue contact duration, whether they are production line equipment or primary packaging and end delivery devices. Victrex also offers unparalleled expertise, experience and support to customers, having been the first to commercialise the use of PEEK over 40 years ago. PEEK materials have properties meeting high levels of physical and chemical performance, ideal for applications requiring sterilisation, retention of dimensional stability, or chemical, electrical and temperature resistance. PEEK also meets high levels of mechanical performance, perfectly suited for high strength and miniature parts, wear, abrasion and fatigue exposure. It is also versatile for thermoplastic processing through moulding processes, milling or additive manufacturing. Victrex offer a unique perspective on this market as their medical business, Invibio, has over 20 years of proven clinical history in implantable medical PEEK devices. This insight and experience have enabled them to become a key player in the drug delivery device space over recent years. They are well placed to collaborate with OEMs, engineers and pharma manufacturing companies to support them from design, regulatory approval, manufacture and beyond. 공시 • Jul 07
Victrex plc to Report Q4, 2023 Results on Dec 04, 2023 Victrex plc announced that they will report Q4, 2023 results on Dec 04, 2023 공시 • Dec 06
Victrex plc, Annual General Meeting, Feb 10, 2023 Victrex plc, Annual General Meeting, Feb 10, 2023.